mirabegron
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pharmacokinetics of Mirabegron
Conditions
Pharmacokinetics of Mirabegron, Food Effect, Healthy Chinese Subjects
Trial Timeline
Sep 21, 2020 → Oct 27, 2020
NCT ID
NCT04501640About mirabegron
mirabegron is a approved stage product being developed by Astellas Pharma for Pharmacokinetics of Mirabegron. The current trial status is completed. This product is registered under clinical trial identifier NCT04501640. Target conditions include Pharmacokinetics of Mirabegron, Food Effect, Healthy Chinese Subjects.
What happened to similar drugs?
4 of 4 similar drugs in Pharmacokinetics of Mirabegron were approved
Approved (4) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05621616 | Phase 3 | Active |
| NCT04562090 | Approved | Completed |
| NCT04501640 | Approved | Completed |
| NCT02981459 | Approved | Withdrawn |
| NCT02916693 | Phase 1/2 | Completed |
| NCT02751931 | Phase 3 | Completed |
| NCT02526979 | Phase 1 | Completed |
| NCT02495389 | Approved | Completed |
| NCT02211846 | Phase 1 | Completed |
| NCT01898624 | Pre-clinical | Completed |
| NCT02570035 | Pre-clinical | Completed |
| NCT00939757 | Phase 1 | Completed |
| NCT01285596 | Phase 1 | Completed |
| NCT01579461 | Phase 1 | Completed |
Competing Products
20 competing products in Pharmacokinetics of Mirabegron